SPY425.10+2.50 0.59%
DIA341.98+3.20 0.94%
IXIC14,369.71+97.98 0.69%

Significant Insider Sales Reported in Shares of Bristol-Myers Squibb (BMY) Extending the Trend of Last Quarter

05/10/2021 18:24

10:20 PM EDT, 05/10/2021 (MT Newswires) -- SEC filings today revealed substantial insider sales of Bristol-Myers Squibb shares as two insiders -- Dr Rupert Vessey, Officer, and Adam Dubow, Officer -- disposed of 33,665 shares in the company having a market value of approximately $2,164,073. There was one insider buy/sell transaction in the past 90 days prior to these transactions which resulted in the sale of 25,000 shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 58,665 shares and have averaged 19,555 shares per transaction over this time period.

Today's Insider Activity

The number of insider buy/sell trades at Bristol-Myers Squibb is greater than that of the 150 peer company average over the last 90-day period. The Pharmaceuticals peer group saw 96 buy/sell trades during this period for an average of 0.6 transactions per company. However, the number of shares traded per transaction by Bristol-Myers Squibb insiders is lower than its peers. Within the peer group there were 1,531,389 shares purchased and 2,018,102 shares sold with company insiders selling 5,070 shares on average over this time period.

The data used in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

[Disclaimer]
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.